CN1203089C - 新化合物 - Google Patents

新化合物 Download PDF

Info

Publication number
CN1203089C
CN1203089C CNB95196643XA CN95196643A CN1203089C CN 1203089 C CN1203089 C CN 1203089C CN B95196643X A CNB95196643X A CN B95196643XA CN 95196643 A CN95196643 A CN 95196643A CN 1203089 C CN1203089 C CN 1203089C
Authority
CN
China
Prior art keywords
phenyl
nmr
alkoxy
preparation
apci
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CNB95196643XA
Other languages
English (en)
Chinese (zh)
Other versions
CN1168675A (zh
Inventor
大木秀德
富岛昌纪
山田明
高杉寿
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yamanouchi Pharmaceutical Co Ltd
Original Assignee
Fujisawa Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26305774&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1203089(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB9420425A external-priority patent/GB9420425D0/en
Priority claimed from GBGB9508745.8A external-priority patent/GB9508745D0/en
Application filed by Fujisawa Pharmaceutical Co Ltd filed Critical Fujisawa Pharmaceutical Co Ltd
Publication of CN1168675A publication Critical patent/CN1168675A/zh
Application granted granted Critical
Publication of CN1203089C publication Critical patent/CN1203089C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
CNB95196643XA 1994-10-07 1995-09-29 新化合物 Expired - Lifetime CN1203089C (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB9420425.2 1994-10-07
GB9420425A GB9420425D0 (en) 1994-10-07 1994-10-07 New compound
GBGB9508745.8A GB9508745D0 (en) 1995-04-28 1995-04-28 New compound
GB9508745.8 1995-04-28

Publications (2)

Publication Number Publication Date
CN1168675A CN1168675A (zh) 1997-12-24
CN1203089C true CN1203089C (zh) 2005-05-25

Family

ID=26305774

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB95196643XA Expired - Lifetime CN1203089C (zh) 1994-10-07 1995-09-29 新化合物

Country Status (26)

Country Link
US (2) US6107458A (cg-RX-API-DMAC10.html)
EP (1) EP0788511B1 (cg-RX-API-DMAC10.html)
JP (2) JP2897427B2 (cg-RX-API-DMAC10.html)
KR (1) KR100353303B1 (cg-RX-API-DMAC10.html)
CN (1) CN1203089C (cg-RX-API-DMAC10.html)
AR (1) AR041770A1 (cg-RX-API-DMAC10.html)
AT (1) ATE229541T1 (cg-RX-API-DMAC10.html)
AU (1) AU696949B2 (cg-RX-API-DMAC10.html)
BR (2) BR9504791B1 (cg-RX-API-DMAC10.html)
CA (1) CA2202058C (cg-RX-API-DMAC10.html)
DE (2) DE69529172T2 (cg-RX-API-DMAC10.html)
DK (1) DK0788511T3 (cg-RX-API-DMAC10.html)
ES (1) ES2187575T3 (cg-RX-API-DMAC10.html)
FI (1) FI119988B (cg-RX-API-DMAC10.html)
FR (1) FR08C0028I2 (cg-RX-API-DMAC10.html)
HU (1) HU228151B1 (cg-RX-API-DMAC10.html)
IL (1) IL115484A (cg-RX-API-DMAC10.html)
LU (1) LU91452I2 (cg-RX-API-DMAC10.html)
MX (1) MX9702531A (cg-RX-API-DMAC10.html)
NL (1) NL300352I2 (cg-RX-API-DMAC10.html)
NO (2) NO328483B1 (cg-RX-API-DMAC10.html)
OA (1) OA10475A (cg-RX-API-DMAC10.html)
PT (1) PT788511E (cg-RX-API-DMAC10.html)
RU (1) RU2165423C2 (cg-RX-API-DMAC10.html)
TR (1) TR199501229A2 (cg-RX-API-DMAC10.html)
WO (1) WO1996011210A1 (cg-RX-API-DMAC10.html)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5696084A (en) * 1996-08-16 1997-12-09 Abbott Laboratories Amino-lipopetide antifungal agents
AUPO371596A0 (en) * 1996-11-19 1996-12-12 Fujisawa Pharmaceutical Co., Ltd. New compound
AUPO381496A0 (en) * 1996-11-25 1996-12-19 Fujisawa Pharmaceutical Co., Ltd. New compound
EP0994101A4 (en) * 1997-06-18 2002-05-02 Fujisawa Pharmaceutical Co NEW PREPARATION PROCESS
US6232290B1 (en) * 1998-02-09 2001-05-15 Fujisawa Pharmaceutical Co., Ltd. Cyclic hexapeptides with antimicrobial activity
AU756792B2 (en) * 1998-02-09 2003-01-23 Fujisawa Pharmaceutical Co., Ltd. New compound
EP1156787B1 (en) * 1999-02-11 2005-11-30 Emisphere Technologies, Inc. Oxadiazole compounds and compositions for delivering active agents
US7084279B1 (en) * 1999-02-11 2006-08-01 Emisphere Technologies Inc. Oxadiazole compounds and compositions for delivering active agents
AUPP999799A0 (en) * 1999-04-27 1999-05-20 Fujisawa Pharmaceutical Co., Ltd. New compound
AUPQ066399A0 (en) * 1999-05-31 1999-06-24 Fujisawa Pharmaceutical Co., Ltd. Antifungal combination use
TWI233805B (en) * 1999-07-01 2005-06-11 Fujisawa Pharmaceutical Co Stabilized pharmaceutical composition in lyophilized form as antifungal agent
CA2380176A1 (en) 1999-07-27 2001-02-01 Aventis Pharma Deutschland Gmbh Novel cyclohexapeptide compounds, processes for their production and their use as a pharmaceutical
AUPQ462399A0 (en) * 1999-12-13 2000-01-13 Fujisawa Pharmaceutical Co., Ltd. New use
TWI250992B (en) * 2000-02-21 2006-03-11 Astellas Pharma Inc Polypeptide compounds for the prophylactic and/or therapeutic treatment of infectious diseases caused by pathogenic microorganisms
ES2191516B1 (es) * 2000-07-28 2005-01-01 Consejo Superior De Investigaciones Cientificas Antibioticos antifungicos de naturaleza peptidica inhibidores de la germinacion y el crecimiento de hongos fitopatogenos.
AUPQ938700A0 (en) * 2000-08-14 2000-09-07 Fujisawa Pharmaceutical Co., Ltd. Antifungal combination use
KR100777169B1 (ko) 2001-01-29 2007-11-16 시오노기세이야쿠가부시키가이샤 5-메틸-1-페닐-2-(1ｈ)-피리돈을 활성 성분으로서함유하는 의약 제제
JP2005053782A (ja) * 2001-08-31 2005-03-03 Fujisawa Pharmaceut Co Ltd 環状リポペプチド化合物の新規結晶
AU2003217676B2 (en) 2002-02-22 2009-06-11 Takeda Pharmaceutical Company Limited Active agent delivery systems and methods for protecting and administering active agents
JP4784093B2 (ja) * 2002-08-08 2011-09-28 アステラス製薬株式会社 イソオキサゾリル安息香酸の製造法
AU2003903205A0 (en) * 2003-06-23 2003-07-10 Fujisawa Pharmaceutical Co., Ltd. New compound
WO2005018743A1 (en) 2003-07-22 2005-03-03 Theravance, Inc. Use of an echinocandin antifungal agent in combination with a glycopeptide antibacterial agent
US20070010655A1 (en) * 2003-09-05 2007-01-11 Antia Firoz D Stationary phases and a purification process using the stationary phases
EP1669350B1 (en) * 2003-09-22 2012-02-29 Msd K.K. Piperidine derivatives
US7476673B2 (en) * 2003-12-30 2009-01-13 Allergan, Inc. Disubstituted chalcone oximes as selective agonists of RARγ retinoid receptors
CN101198598A (zh) * 2004-05-20 2008-06-11 弗尔德里克斯制药股份有限公司 2-((杂)芳基)-苯并噁唑化合物及其衍生物、组合物以及用于稳定和抑制甲状腺素转运蛋白错重叠的方法
CA2580856A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
CN101084212A (zh) 2004-09-20 2007-12-05 泽农医药公司 杂环衍生物及其作为硬脂酰CoA去饱和酶介导剂的用途
CA2580855A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
CA2580845A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase
EP1799667B1 (en) 2004-09-20 2013-03-20 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as therapeutic agents
EP1804799B1 (en) 2004-09-20 2013-08-21 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
EP1830837B1 (en) 2004-09-20 2013-09-04 Xenon Pharmaceuticals Inc. Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-coa desaturase enzymes
WO2006044456A1 (en) * 2004-10-13 2006-04-27 Ptc Therapeutics, Inc. Compounds for nonsense suppression, and methods for their use
MX2007015216A (es) 2005-06-03 2008-02-22 Xenon Pharmaceuticals Inc Derivados de aminotiazol y sus usos como agentes terapeuticos.
WO2007043400A1 (ja) * 2005-10-07 2007-04-19 Kissei Pharmaceutical Co., Ltd. 含窒素芳香族複素環化合物およびそれを含有する医薬組成物
CN101516387B (zh) * 2006-07-26 2014-06-04 桑多斯股份公司 卡泊芬净制剂
US8853392B2 (en) 2007-06-03 2014-10-07 Vanderbilt University Benzamide mGluR5 positive allosteric modulators and methods of making and using same
EP2184989B1 (en) 2007-08-13 2015-05-06 Monsanto Technology LLC Compositions and methods for controlling nematodes
RU2470939C2 (ru) * 2007-10-29 2012-12-27 Астеллас Фарма Инк. Полипептидное соединение
US8034806B2 (en) 2007-11-02 2011-10-11 Vanderbilt University Bicyclic mGluR5 positive allosteric modulators and methods of making and using same
US8362050B2 (en) * 2008-06-24 2013-01-29 Irm Llc Compounds and methods for modulating G protein-coupled receptors
US9394340B2 (en) 2009-03-24 2016-07-19 Cadila Healthcare Limited Purification process for lipopeptides
BR112013023531A2 (pt) 2011-04-04 2016-12-06 Xellia Pharmaceuticals Aps processo de um único vaso para a fabricação de micafungina ou de um sal desta
US9132163B2 (en) 2011-04-20 2015-09-15 Xellia Pharmaceuticals Aps Method for purification of Micafungin
CN102775476B (zh) * 2011-05-12 2015-01-07 上海天伟生物制药有限公司 一种米卡芬净钠盐的制备方法
EP2709609B1 (en) 2011-05-17 2017-10-04 Shionogi & Co., Ltd. Heterocyclic compounds
KR20140069097A (ko) * 2011-09-09 2014-06-09 산도즈 아게 미카펀진 중간체의 제조
CN102627689B (zh) * 2012-03-30 2014-08-06 上海天伟生物制药有限公司 一种环肽类化合物的水合物及其制备方法和用途
CN102659930B (zh) 2012-03-30 2014-04-23 上海天伟生物制药有限公司 一种高纯度环肽类物质的晶体及其制备方法和用途
CN102627688B (zh) 2012-03-30 2014-12-31 上海天伟生物制药有限公司 一种高纯度环肽化合物及其制备方法和用途
JP7109189B2 (ja) * 2014-05-29 2022-07-29 シャンハイ テックウェル バイオファーマシューティカル カンパニー リミテッド シクロペプチド系化合物の組成物およびその製造方法と使用
JP6491325B2 (ja) * 2014-05-29 2019-03-27 シャンハイ テックウェル バイオファーマシューティカル カンパニー リミテッドＳｈａｎｇｈａｉ Ｔｅｃｈｗｅｌｌ Ｂｉｏｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．，Ｌｔｄ シクロペプチド系化合物の溶媒和物およびその製造方法と使用
EP3226885A4 (en) * 2014-10-07 2018-07-18 Alaparthi, Lakshmi Prasad Intermediates and processes to prepare micafungin
CA2937365C (en) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
AU2017376960B2 (en) 2016-12-16 2023-12-14 Baxter Healthcare Sa Micafungin compositions
EP3485873A1 (en) 2017-11-17 2019-05-22 Cadila Healthcare Limited Stable pharmaceutical injectable compositions of micafungin
CN108752430B (zh) * 2018-05-31 2022-02-18 杭州中美华东制药有限公司 米卡芬净钠新晶型及其制备方法
WO2020013116A1 (ja) * 2018-07-10 2020-01-16 京都薬品工業株式会社 Ｐｔｐ－１ｂ阻害剤およびその用途
CN110734408A (zh) * 2019-10-22 2020-01-31 重庆康乐制药有限公司 一种米卡芬净类衍生物侧链中间体的制备方法
CN115785226A (zh) * 2021-09-09 2023-03-14 上海天伟生物制药有限公司 一种棘白菌素药物杂质及其制备、纯化方法和应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1574603A1 (ru) * 1988-08-11 1990-06-30 Ивановский Химико-Технологический Институт Способ получени мезо-тетраарилоктаметилпорфиринов
IE912046A1 (en) * 1990-06-18 1991-12-18 Fujisawa Pharmaceutical Co New polypeptide compound and a process for preparation¹thereof
IL122315A (en) * 1992-03-19 2002-03-10 Lilly Co Eli Cyclic peptides and antifungal pharmaceutical compositions containing them

Also Published As

Publication number Publication date
NL300352I2 (nl) 2008-11-03
AR041770A1 (es) 2005-06-01
NO971544D0 (no) 1997-04-04
IL115484A (en) 2000-07-16
BRPI9504791B8 (pt) 2019-12-31
NO971544L (no) 1997-06-04
DE122008000025I1 (de) 2008-08-21
NO328483B1 (no) 2010-03-01
EP0788511A1 (en) 1997-08-13
DK0788511T3 (da) 2003-03-31
PT788511E (pt) 2003-04-30
US6107458A (en) 2000-08-22
US6265536B1 (en) 2001-07-24
ATE229541T1 (de) 2002-12-15
BR9504791B1 (pt) 2010-10-05
JPH10507174A (ja) 1998-07-14
MX9702531A (es) 1997-06-28
NO2010016I1 (no) 2010-08-16
LU91452I2 (fr) 2008-08-04
WO1996011210A1 (en) 1996-04-18
JP3518665B2 (ja) 2004-04-12
CN1168675A (zh) 1997-12-24
IL115484A0 (en) 1996-01-19
HUT77736A (hu) 1998-07-28
AU3578095A (en) 1996-05-02
CA2202058C (en) 2007-11-06
NL300352I1 (nl) 2008-08-01
FI971397L (fi) 1997-05-27
DE69529172D1 (de) 2003-01-23
TR199501229A2 (tr) 1996-07-21
FI971397A0 (fi) 1997-04-04
BR9504791A (pt) 1996-10-22
CA2202058A1 (en) 1996-04-18
KR100353303B1 (ko) 2003-01-15
EP0788511B1 (en) 2002-12-11
FR08C0028I2 (cg-RX-API-DMAC10.html) 2009-11-20
FI119988B (fi) 2009-05-29
RU2165423C2 (ru) 2001-04-20
JPH10324695A (ja) 1998-12-08
AU696949B2 (en) 1998-09-24
KR970707150A (ko) 1997-12-01
HK1004136A1 (en) 1998-11-20
DE69529172T2 (de) 2003-04-17
JP2897427B2 (ja) 1999-05-31
DE122008000025I2 (de) 2011-02-17
HU228151B1 (en) 2012-12-28
FR08C0028I1 (cg-RX-API-DMAC10.html) 2008-08-15
OA10475A (en) 2002-04-08
NO2010016I2 (no) 2011-10-17
ES2187575T3 (es) 2003-06-16

Similar Documents

Publication Publication Date Title
CN1203089C (zh) 新化合物
CN1240713C (zh) 化合物
CN1040541C (zh) 新型多肽化合物的制备方法
CN1225471C (zh) 具有生长激素释放特性的化合物
CN1289500C (zh) 氮杂双环化合物,它们的制备方法以及它们作为药物的应用,特别地作为抗菌剂的应用
CN1198839C (zh) 作为凝血酶抑制剂的新的二肽脒类
CN1027271C (zh) 正斯塔提尼及正环斯塔提尼多肽的制备方法
CN1038939C (zh) 肽类化合物的制备方法
CN1192773C (zh) 环胺ccr3拮抗剂
CN1247544C (zh) 带有杂芳基磺酰基侧链的邻氨基苯甲酰胺及其作为抗心律失常活性物质的用途
CN1057306C (zh) 新的多肽化合物及其制备方法
CN1198804C (zh) 酰胺化合物及其用途
CN1066660A (zh) 新的肽化合物及其制备方法
CN1568187A (zh) 2h－2,3－二氮杂萘－1－酮和其使用方法
CN1327443A (zh) 取代的酰苯胺化合物
CN1118595A (zh) 氨茴酸衍生物
CN1276785A (zh) N－烷酰基苯丙氨酸衍生物
CN1237978A (zh) N－(芳基/杂芳基)氨基酸衍生物、包括这些衍生物的药用组合物以及用这些化合物抑制β－淀粉样肽释放和或其合成的方法
CN1281430A (zh) 芳酰基苯丙氨酸衍生物
CN1474809A (zh) 氰基吡咯烷衍生物
CN1469871A (zh) 作为生长激素促分泌素的取代的二肽
CN1247542A (zh) 丝氨酸蛋白酶抑制剂
CN1560051A (zh) 取代吡唑化合物
CN1764648A (zh) 作为组蛋白脱乙酰酶(hdac)抑制剂的异羟肟酸衍生物
CN1204889C (zh) 粘附受体拮抗剂

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C56 Change in the name or address of the patentee

Owner name: ASTELLAS PHARMA INC.

Free format text: FORMER NAME OR ADDRESS: FUJISAWA PHARMACEUTICAL CO., LTD.

CP03 Change of name, title or address

Address after: Tokyo, Japan

Patentee after: Yamanouchi Pharma Co., Ltd.

Address before: Osaka City, Osaka of Japan

Patentee before: Fujisawa Pharmaceutical Co., Ltd.

CX01 Expiry of patent term

Granted publication date: 20050525

EXPY Termination of patent right or utility model